Cyteph

Executive Summary

Cyteph Pty Ltd is an Australian biotechnology company focused on developing off-the-shelf allogeneic T-cell therapies for solid tumors, with an initial focus on glioblastoma. The company's proprietary Cyt-ATTAC platform enables dual-targeting CAR-T products that leverage cytomegalovirus (CMV)-specific T cells to enhance persistence and tumor targeting. By utilizing HLA-matched patient selection and rapid manufacturing, Cyteph aims to overcome key limitations of current CAR-T therapies, including scalability, cost, and efficacy in solid tumors. Founded in 2020 and based in Herston, Australia, the company has raised $1.5 million and is currently in the phase 1 stage of development. Cyteph's approach addresses a significant unmet need in oncology, particularly for glioblastoma, where treatment options are limited and outcomes remain poor. The company's early-stage pipeline and focus on allogeneic therapies position it within a competitive but rapidly evolving field, with potential for differentiation through its unique CMV-targeting strategy.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1 Clinical Trial for Glioblastoma Candidate60% success
• Q2 2026Presentation of Preclinical Data at Major Oncology Conference75% success
• Q4 2026Announcement of Series A Funding or Strategic Partnership40% success